Mirjam Stahl

38PUBLICATIONS
74CO-AUTHORS
Carbon capture engineering (excl. sequestration)Fluid-structure interaction and aeroacousticsStructural properties of condensed matterRespiratory diseasesInfant and child health
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (38)

|May 13, 2026
Off-label treatment with elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: real-world evidence from the German CF Registry.

|Sep 18, 2025
Reduction of systemic inflammation by elexacaftor/tezacaftor/ivacaftor correlates with lung function improvement in cystic fibrosis.

Olga Halle, Simon Y Graeber, Julia Kontsendorn

|Sep 18, 2025
Changes in sputum viscoelastic properties and airway inflammation in primary ciliary dyskinesia are comparable to cystic fibrosis on elexacaftor/tezacaftor/ivacaftor therapy.

Hannah Nussstein, Ruth M Urbantat, Kerstin Fentker

|Jun 24, 2025
Multiple-breath washout is more sensitive than spirometry to detect lung function impairment in children and adults with bronchiectasis.

Niklas Ziegahn, Jobst F Roehmel, Charlotte O Pioch

|Jun 17, 2025
Prenatal Elexacaftor/Tezacaftor/Ivacaftor Treatment Prevents Meconium Ileus, but Not Exocrine Pancreatic Insufficiency and Lung Disease in Infants With Cystic Fibrosis.

Paulina E Aleksander, Stephanie Thee, Felix Doellinger

|Jan 21, 2025
Reply to Martin and Grasemann: Is There a Role for Lumacaftor/Ivacaftor in Young Children with Cystic Fibrosis?

Mirjam Stahl, Jobst Röhmel, Mark O Wielpütz

Pageof 7

Frequent Collaborators

28 joint publications

Marcus Alexander Mall

13 joint publications

Simon Y Graeber

9 joint publications

Mark O Wielpütz

8 joint publications

Stephanie Thee